You are here: All Products  > Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor

Ascentage Granted China Priority Review of NDA for BCR-ABL Inhibitor

Price: $5.00
Available

Get instant access to this article for unlimited viewing and/or downloading for seven days.


Back to products